Ferragamo Revenue Falls 6.2% in Third Quarter as Vivendi and Gentian Grow

Key Facts

Salvatore Ferragamo's revenue fell 6.2% in the third quarter of 2026 from the same period a year earlier to 207 million euros, according to the company's disclosure on its first nine months of business. Revenue declined 3.5% at constant exchange rates, compared with the larger decrease reported at current exchange rates for the same quarter. The decline came as wholesale sales fell 24.2% at current exchange rates in the third quarter from a year earlier, according to the disclosure. Total revenue for the first nine months of 2026 was 675 million euros. The direct-to-consumer channel recorded sales of 537 million euros over the same nine-month period, according to figures released by Ferragamo.

By region, Ferragamo's sales in Asia-Pacific fell 11.1% in the third quarter of 2026 from the same period a year earlier at constant exchange rates. North American sales, meanwhile, rose 2.4% on the same basis during the quarter, according to its revenue disclosure. Ferragamo said in its investor presentation that core full-price retail sales rose during the period. It also pointed to positive performance in the United States and Europe, which, together with higher full-price sales, offset weak demand in Asia. In its presentation, the company described the Asian factor as "weak demand across Asia," alongside what it called positive performance in other markets.

In Vivendi's third-quarter 2026 results, group revenue rose 13.8% from the same period a year earlier to 77 million euros, according to RTT News. Its Gameloft subsidiary recorded quarterly revenue of 72 million euros, according to Vivendi's statement on its quarterly and first nine-month results. Gameloft's organic revenue growth was 6.1% compared with the third quarter of 2025, excluding currency effects and changes in the scope of operations. Vivendi owns all of Gameloft's capital, according to Agefi Dow Jones, which reported an ownership stake of 100%. Vivendi shares closed the session on 20 October 2026 down 0.32%, according to RTT News.

Gentian Diagnostics posted record quarterly sales of 51.1 million Norwegian kroner in the third quarter of 2026, according to its results announcement. Sales in the corresponding period of 2025 were about 41.8 million Norwegian kroner, according to the comparison in the quarterly announcement. The company thus reported sales growth of 22% year on year, while organic growth excluding currency effects was 30%. Earnings before interest, taxes, depreciation and amortisation rose to 13.6 million Norwegian kroner from 8.4 million kroner in the third quarter of the previous year. The gross margin rose to 61% during the quarter from 56% in the corresponding period, according to the company's results.

The improvement in Gentian's quarterly results extended to basic earnings per share, which reached 0.48 Norwegian kroner in the third quarter of 2026, according to its quarterly report. Basic earnings per share were 0.26 Norwegian kroner in the third quarter of 2025, according to the comparison in the report. For the first nine months of 2026, the company recorded a cumulative net loss of 8.5 million Norwegian kroner. That compared with a net profit of 9.8 million Norwegian kroner in the first nine months of the previous year. In its Asian business, Gentian's sales for the nine-month period fell 33%, which the company attributed to pricing and testing restrictions in China.

Gentian's nine-month results included an impairment charge of 30.2 million Norwegian kroner, according to details in its third-quarter 2026 report. The item was recorded in the first quarter of the year and was included in the nine-month results. The company said the impairment was non-cash and related to the discontinuation of the "NT-proBNP" test project. In other development projects, Gentian is working on a test for a major partner in in-vitro diagnostics, according to its quarterly results announcement. The company aims to launch the test in the fourth quarter of 2027, according to the target date announced in its business report.